ZUG, Switzerland, June 27, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company purposefully driven to save sight and...
ZUG, Switzerland, June 10, 2024 (GLOBE NEWSWIRE) -- Improvements in multiple sign efficacy endpoints were observed in full population and with predictive and more pronounced effects in the TNFR1...
Oculis is advancing its precision medicine approach to dry eye disease, outlining plans to finalize a phase 3 study after seeing signs of efficacy.
ZUG, Switzerland, June 04, 2024 (GLOBE NEWSWIRE) -- The attached notifications relate to the annual equity incentive awards granted to directors of the Company, as well as the one-time equity...
Shareholders approved all agenda items and proposals of the Board of DirectorsRobert K. Warner, M.B.A. and Arshad M. Khanani, M.D., M.A., FASRS elected as members of the Board of DirectorsBaruch D....
ZUG, May 17, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (Oculis or the Company), a global biopharmaceutical company, has issued registered ordinary shares of the...
Topline results anticipated in Q4 2024 for Phase 2 trial evaluating the safety and tolerability of OCS-05 in patients with Acute Optic Neuritis (AON)Oculis also aims to complete an IND submission for...
ZUG, Switzerland, May 08, 2024 (GLOBE NEWSWIRE) -- Clinical programs progressing as planned with initiation of second OCS-01 Phase 3 DIAMOND-2 trial in Diabetic Macular Edema (DME) and completion of...
Zug, Switzerland, May 07, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq Global Market: OCS) (Oculis), has published the invitation to the 2024 Annual General Meeting, which will be held on...
ZUG, Switzerland, and BOSTON, USA, May 06, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (Oculis or the Company) a global biopharmaceutical company purposefully driven to...